Showing results (1671-1680 of 1,957) with videos related to

Sort By:
Pageof 196
BMJ (Clinical Research Ed.)|October 10, 2019
Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adultsMyriam Alexander, A Katrina Loomis, Johan van der Lei, et al.
Hemasphere|September 13, 2021
Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic CriteriaRebecca L King, Arushi Khurana, Raphael Mwangi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 11, 2013
Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantationAbhishek Singla, William J Hogan, Stephen M Ansell, et al.
American Journal of Hematology|June 17, 2022
Clinical characteristics, prognostic indicators, and survival outcomes in intravascular lymphoma: Mayo Clinic experience (2003-2018)Karan Seegobin, Zhuo Li, Muhamad Alhaj Moustafa, et al.
Blood|April 7, 2021
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study resultsRanjana H Advani, Alison J Moskowitz, Nancy L Bartlett, et al.
Blood|February 4, 2016
Large B-cell transformation in nodular lymphocyte-predominant Hodgkin lymphoma: 40-year experience from a single institutionSaad Sirop Kenderian, Thomas M Habermann, William R Macon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemiaIrene M Ghobrial, Morie Gertz, Betsy Laplant, et al.
Blood|April 30, 2015
The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphomaThomas E Witzig, Craig Reeder, Jing Jing Han, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 7, 2019
Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With ImmunochemotherapyYucai Wang, Umar Farooq, Brian K Link, et al.
Seminars in Hematology|May 17, 2025
Report of Consensus Panel 6 from the 12th International Workshop on Waldenström's Macroglobulinemia on Diagnosis and Management of Transformed Waldenström's MacroglobulinemiaEric Durot, Jithma P Abeykoon, Damien Roos-Weil, et al.
Pageof 196